Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once weekly versus liraglutide once daily in type 2 diabetes
2009-012011-17Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Exenatide once weekly with Liraglutide once daily (2 arms). Primary endpoint: Change in HbA1c. Started Sep 2009; status: completed.
02
Drugs
exenatideliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-012011-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012011-17.